The study provides an in-depth analysis of the Metabolomics market, current trends, and future estimates to elucidate the impending investment pockets.
PORTLAND, OREGON, USA, September 9, 2022 /EINPresswire.com/ — Growing R&D spending in the pharmaceutical and biopharmaceutical industry, availability of public and private funding for metabolomics research, and continuous innovations in metabolomics instruments are driving the growth of the global metabolomics industry.
According to the report published by Allied Market Research, the global metabolomics market was estimated at USD 2.03 billion in 2020 and is projected to reach USD 6.66 billion by 2030, registering a CAGR of 12.2% from 2021 to 2030.
For a good perspective, download a sample PDF at: https://www.alliedmarketresearch.com/request-sample/525
Drivers, constraints and opportunities –
The fact that metabolomics has the ability to detect a large number of metabolites from a sample of liquid or tissue in a single step and can also produce large quantities leads to a large increase in the demand for metabolomics, thus driving the growth of the market. On the other hand, the high cost of metabolomics instruments and the scarcity of professionals are restraining the growth to some extent. However, technological advancements in analytical techniques and increasing R&D spending are expected to create an array of opportunities in the industry.
The growth of the global metabolomics market is driven by increasing prevalence of chronic diseases globally, increasing R&D investment for metabolomics development and increasing demand for personalized medicine. However, the lack of skilled professionals in the field along with the astronomical price of metabolomics instruments is hampering the growth of the market. Nevertheless, the immense potential of metabolomics in disease diagnosis and its growing prospects in human nutrition would create lucrative opportunities for emerging market players in the near future.
Metabolomics bioinformatics tools and services to achieve leadership
On the basis of products and services, the metabolomics bioinformatics tools and services segment is projected to be the largest and fastest growing segment through 2030. This is attributed to the tremendous advancements demonstrated by bioinformatics, which is on the poised to grow even more in the near future through the use of robust algorithms and parameter estimation techniques in life science research and analysis.
Owing to increased adoption of metabolomics in precision medicine and surge in R&D investments, the metabolomics market is expected to grow at a productive rate over the analysis period. Additionally, technological advancements in ancillary medical devices and growing demand for the development of quality drugs are expected to fuel the market. However, the high cost of medical devices and lack of effective data management is hampering the growth of the metabolomics market.
The outbreak of the pandemic has led to huge disruptions in R&D activities, which in turn have had a negative impact on the global metabolomics market.
However, the market has almost recovered, in terms of income.
The metabolomics bioinformatics tools and services segment to retain the lion’s share
Based on products and services, the metabolomics bioinformatics tools and services segment accounted for the highest market share in 2020, generating almost three quarters of the global metabolomics market. The same segment is also expected to cite the fastest CAGR of 12.7% from 2021 to 2030. This is due to the increase in the amount of data generated in metabolomic processes that require proper management through the use of bioinformatics tools.
Do you have a specific question or requirement? Ask our industry expert: https://www.alliedmarketresearch.com/purchase-enquiry/525
The biomarker discovery segment to lead the trail-
Based on applications, the biomarker discovery segment generated the highest share in 2020, holding more than two-fifths of the global metabolomics market, owing to the sharp increase in the prevalence of cancer. The personalized medicine segment, however, is expected to cite the fastest CAGR of 15.6% from 2021 to 2030. Rising awareness related to the use of personalized medicine and the extensive use of metabolomics in these stimulate the growth of the segment.
North America will dominate by 2030-
Based on region, North America contributed the leading market share in terms of 2020 revenue, holding more than two-fifths of the global metabolomics market, due to the increase in research activities involving the use of metabolomics. Asia-Pacific, on the other hand, is expected to quote the fastest CAGR of 13.9% from 2021 to 2030. This is due to increased awareness in the use of metabolomics.
Major Market Players-
Bio-Rad Laboratories INC.
Agilent Technologies Inc.
Human Metabolism Technologies INC.
BiocratesLife Science AG
We also offer regional and national reports –
Japanese metabolomics market
South Korea metabolomics market
Singapore Metabolomics Market
Chinese metabolomics market
Metabolomics market in Indonesia
Australian metabolomics market
Taiwan Metabolomics Market
“We have also published some syndicated market studies in the same field that you may be interested in. Below is the title of the report for your reference, considering the impact of Covid-19 on this market, which will help you to assess the impact of the pandemic on the short and long-term growth trends of this market.
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business consulting division of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global corporations as well as small and medium enterprises with unparalleled quality of “market research reports” and “business intelligence solutions”. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market areas. AMR offers its services across 11 verticals, including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverage, Energy & Power, semiconductors and electronics, automotive and transport, ICT and media, aerospace and defense and BFSI.